## HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCI	RIBER		PATIENT:
Name:			Name:
Ward: .			NHI:
Nintedanib			
INITIAT Re-assi Prereq and a	rion – i essmer uisites	Patient has been diagnosed with idiopathic pulmonary fibrosis  Forced vital capacity is between 50% and 90% predicted  Nintedanib is to be discontinued at disease progression (See Nintedanib is not to be used in combination with subsidised pin  The patient has not previously received treatment with p  Patient has previously received pirfenidone, but disconting	Note)  rfenidone  irfenidone  nued pirfenidone within 12 weeks due to intolerance ent's disease has not progressed (disease progression defined as 10%
CONTINUATION – idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate)  O Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.  and  O Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment  O Nintedanib is not to be used in combination with subsidised pirfenidone and  O Nintedanib is to be discontinued at disease progression (See Note)			
Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.			